Results 31 to 40 of about 616,871 (170)

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia

Molecular Cancer, 2023
Pharmacologic targeting of chromatin-associated protein complexes has shown significant responses in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) but resistance frequently develops to single agents.
Nuria Tubío-Santamaría, Ashok Kumar Jayavelu, Tina M. Schnoeder, Theresa Eifert, Chen-Jen Hsu, Florian Perner, Qirui Zhang, Daniela V. Wenge, Fynn M. Hansen, Joanna M. Kirkpatrick, Nidhi Jyotsana, Steven W. Lane, Björn von Eyss, Aniruddha J. Deshpande, Michael W. M. Kühn, Juerg Schwaller, Clemens Cammann, Ulrike Seifert, Frédéric Ebstein, Elke Krüger, Andreas Hochhaus, Michael Heuser, Alessandro Ori, Matthias Mann, Scott A. Armstrong, Florian H. Heidel   +25 more
doaj   +1 more source

Karin Smirnoff: Sitten menin kotiin

, 2022
Arvio teoksesta Karin Smirnoff: Sitten menin kotiin (Sen for jag hem). Suom. Outi Menna. Tammi 2022.
Vaismaa, Riitta
core   +1 more source

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer

Breast Cancer Research, 2022
Background Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies.
Annamaria Salvati, Viola Melone, Assunta Sellitto, Francesca Rizzo, Roberta Tarallo, Tuula A. Nyman, Giorgio Giurato, Giovanni Nassa, Alessandro Weisz   +8 more
doaj   +1 more source

The clinical impact of the molecular landscape of acute myeloid leukemia

Haematologica, 2023
Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has led to remarkable advances in our understanding of the disease. Mutations now allow us to explore the enormous diversity among cytogenetically defined subsets of AML,
Sabine Kayser, Mark J. Levis
doaj   +1 more source

Revumenib for patients with acute leukemia: a new tool for differentiation therapy

Haematologica
Treatment of acute leukemia is gradually moving away from a “one-size-fits-all” approach, as scientific and clinical advances expand the arsenal of available targeted therapies.
Meira Yisraeli Salman, Eytan M. Stein
doaj   +1 more source

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia

Journal of Hematology & Oncology, 2019
Introduction The chromosomal rearrangements of the mixed-lineage leukemia gene MLL (KMT2A) have been extensively characterized as a potent oncogenic driver in leukemia.
Krzysztof Brzezinka, Ekaterina Nevedomskaya, Ralf Lesche, Michael Steckel, Ashley L. Eheim, Andrea Haegebarth, Carlo Stresemann   +6 more
doaj   +1 more source

Targeted therapy in NPM1-mutated AML: Knowns and unknowns

Frontiers in Oncology, 2022
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by malignant proliferation of myeloid hematopoietic stem/progenitor cells. NPM1 represents the most frequently mutated gene in AML and approximately 30% of AML cases carry NPM1 ...
Rong Wang, Rong Wang, Pan Xu, Lin-Lin Chang, Shi-Zhong Zhang, Hong-Hu Zhu, Hong-Hu Zhu, Hong-Hu Zhu, Hong-Hu Zhu, Hong-Hu Zhu, Hong-Hu Zhu   +10 more
doaj   +1 more source

Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer

Cell Reports Medicine
Summary: KAT6A is a histone acetyltransferase that is emerging as a therapeutic target in cancer, including estrogen receptor-positive (ER+) breast cancer.
Sarah Naomi Olsen, Bryn Anderson, Charlie Hatton, Zhengtao Chu, Christopher Simpkins, Yanhe Wen, Wallace Bourgeois, Elena L. Haarer, Myles Brown, Rinath Jeselsohn, Alana L. Welm, Eneda Toska, Scott A. Armstrong   +12 more
doaj   +1 more source

A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective

npj Systems Biology and Applications, 2023
Pancreatic neuroendocrine tumors (PanNETs) are a rare tumor entity with largely unpredictable progression and increasing incidence in developed countries.
Silke D. Werle, Nensi Ikonomi, Ludwig Lausser, Annika M. T. U. Kestler, Felix M. Weidner, Julian D. Schwab, Julia Maier, Malte Buchholz, Thomas M. Gress, Angelika M. R. Kestler, Hans A. Kestler   +10 more
doaj   +1 more source

Dysregulation of the tumor suppressor Menin and its target Bach2 in HTLV-1 infection

Retrovirology
Background The tumor suppressor Menin, prone to mutations in both hereditary and sporadic endocrine tumors, along with its direct target Bach2, plays a crucial role in preventing autoimmunity by regulating CD4 + T cell senescence and maintaining cytokine
Hiroe Sejima, Tadasuke Naito, Takuya Fukushima, Mineki Saito   +3 more
doaj   +1 more source